Clinical Trials

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07069595 2026-04-13

PREDICT-RD

78 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04841148 2026-04-09

PALAVY

96 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT07392970 2026-04-09

Motixafortide for MRD Sensitization in AML

10 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07517705 2026-04-08

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

50 enrolled

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT05735717 2026-04-06

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

CNSClassical hematologyLymphoidOther hematologic neoplasm

70 enrolled

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT07136077 2026-04-06

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Phase 2 Active not recruiting

20 enrolled

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT03516279 2026-04-03

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT07507318 2026-04-02

DEL-MRD-CHID

69 enrolled

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07134088 2026-03-30

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

104 enrolled

Phase 1/2 Not yet recruiting

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT07247201 2026-03-30

AlloNK1

31 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm, Residual

NCT05232916 2026-03-19

FLAMINGO-01

Phase 3 Recruiting

750 enrolled

LymphoidMyeloidOther hematologic neoplasm

Breast Neoplasms, Neoplasm, Residual

NCT03494569 2026-03-18

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Phase 1 Suspended

36 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06500273 2026-03-18

ALPHA3

250 enrolled

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT05690984 2026-03-16

EMAT

30 enrolled

Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT06134375 2026-03-12

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

204 enrolled

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06951646 2026-03-09

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Phase 2 Active not recruiting

70 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

119 enrolled

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT05708235 2026-03-05

MiRaDoR

976 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

46 enrolled

Pathologic Complete Response, Neoplasm, Residual

NCT07443592 2026-03-02

LAL-2025

LymphoidOther hematologic neoplasm

330 enrolled

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07441291 2026-02-27

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

Phase 3 Recruiting

70 enrolled

Tumor-Agnostic

Neoplasm, Residual

NCT07413146 2026-02-17

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

100 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm, Residual

NCT05987696 2026-02-11

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Phase 1 Completed

2 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07148180 2026-02-05

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

31 enrolled

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT05429320 2026-02-02

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

37 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT06693830 2026-01-23

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Phase NA Recruiting

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT02389517 2026-01-22

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Phase 2 Completed

42 enrolled 11 charts

Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT07350824 2026-01-20

Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

276 enrolled

Recurrence, Neoplasm, Residual

NCT06358430 2026-01-15

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

42 enrolled

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT07025785 2026-01-15

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

Phase NA Recruiting

100 enrolled

Breast Neoplasms, Lymphatic Metastasis, Neoplasm, Residual

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Phase NA Active not recruiting

Plasma cell

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT06744075 2025-12-30

CELERITY

108 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Neoplasm, Residual

NCT05929222 2025-12-24

FIL_GAZEBO

Phase 3 Recruiting

190 enrolled

Lymphoma, Lymphoma, Follicular, Neoplasm, Residual

NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

LymphoidOther hematologic neoplasm

23 enrolled

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07280494 2025-12-12

S101MRD

18 enrolled

Phase 2/3 Not yet recruiting

Lymphoma, Neoplasm, Residual

NCT07264010 2025-12-04

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

87 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07257380 2025-12-02

MRD-ATLAS

LymphoidOther hematologic neoplasm

90 enrolled

Tumor-Agnostic

Neoplasm, Residual

NCT07178847 2025-12-01

NeckTAR-IN

Phase NA Recruiting

59 enrolled

Tumor-Agnostic

Neoplasm, Residual

NCT02666898 2025-11-26

ICLL07GAI

Phase 2 Completed

135 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

NCT04707300 2025-11-20

HTLP-ONCO

10 enrolled

Phase 1 Active not recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT03233854 2025-11-18

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

56 enrolled

Burkitt Lymphoma, Neoplasm, Residual

NCT03326921 2025-11-14

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

LymphoidMyeloidOther hematologic neoplasm

24 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Blast Crisis, Leukemia, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT07059975 2025-11-04

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Phase EARLY_PHASE1 Recruiting

36 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06828991 2025-10-20

GOLD